GB0139, Galecto’s lead compound to treat various fibrotic diseases of the lungs, has shown strong anti-fibrotic activity in a mouse model of idiopathic pulmonary fibrosis (IPF) and in IPF patients in a completed Phase 2a trial. A randomized, double-blind and placebo controlled Phase 2b trial (NCT03832946)…
News
Loss of NEDD4-2 — a protein involved in the regulation of airway hydration and mucus clearance — leads to the onset and development of typical manifestations of idiopathic pulmonary fibrosis (IPF) in adult mice, a study has found. These findings, along with the establishment of a new animal…
Severe fatigue is common among people with idiopathic pulmonary fibrosis (IPF) and pulmonary sarcoidosis, and is associated with worse shortness of breath, depression, catastrophizing, and quality of life, a new study suggests. The study, “Severe Fatigue is Highly Prevalent in Patients with IPF or…
Mechanical ventilation is associated with higher mortality rates in hospitalized patients with idiopathic pulmonary fibrosis (IPF) and acute respiratory failure who previously received high-flow nasal cannula oxygen therapy, study says. Future studies are needed to establish strategies for patients to safely transition from oxygen therapy to…
Avalyn Pharma announced that it has raised $35.5 million in Series B funding to expand its pipeline and support clinical trials into AP01, its investigational inhalation treatment for idiopathic pulmonary fibrosis (IPF) and chronic lung allograft dysfunction (CLAD). The company also reported recently completing enrollment for a clinical…
A cell therapy based on human and rat lung progenitor cells — called lung spheroid cells — reduced scarring (fibrosis) when infused in two rat models of pulmonary fibrosis (PF), a study has found. The safety and efficacy of human LSCs is expected to be tested in a Phase…
While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their homes, one may be a new appreciation of telemedicine. “If something good could come out of this crisis, it’s that…
Despite the COVID-19 outbreak, patient enrollment in the Phase 2 trial of setanaxib, an investigational oral treatment for idiopathic pulmonary fibrosis (IPF), is still expected to start by mid-year, Genkyotex, the therapy’s developer, announced in a press release. The single-site study (NCT03865927), whose protocol has been…
FFF Enterprises and Bionews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help them connect as a community and continue to manage their health during this time when many are finding themselves alone. Recognized as the nation’s leading supplier of…
Veracyte has acquired the rights to a gene signature that may serve as a tool, based on a simple blood sample, for determining likely disease outcomes for people with idiopathic pulmonary fibrosis (IPF). The noninvasive blood-based 52-gene signature, developed by researchers at Yale University, will be offered as a complement…
